Breast Imaging

What Is the First Imaging Study for a Palpable Breast Mass in a Pregnant Patient Over 30?

·
What Is the First Imaging Study for a Palpable Breast Mass in a Pregnant Patient Over 30?

A 34-year-old patient, 22 weeks pregnant with her second child, presents to your clinic for a routine visit but mentions a new, tender lump she felt in her left breast last week. On examination, you confirm a firm, mobile, 2 cm mass in the upper outer quadrant. The finding is new, and the patient is understandably anxious. The immediate clinical question is clear: what is the safest and most effective initial imaging study to evaluate this palpable mass in the setting of pregnancy? This article provides a focused workflow for this exact scenario, based on the American College of Radiology (ACR) Appropriateness Criteria, which rates breast ultrasound as a ‘Usually Appropriate’ first step.

Who Fits This Clinical Scenario?

This guidance is specifically for a pregnant female, aged 30 years or older, who presents with a new focal breast pain or a palpable breast mass requiring initial imaging. The key inclusion criteria are the patient’s age (30+), pregnancy status, and the presence of a focal, tangible finding discovered either by the patient or a clinician. The physiologic changes of pregnancy—including increased breast density, vascularity, and glandular proliferation—create a unique diagnostic challenge that this workflow addresses.

It is crucial to distinguish this presentation from similar but distinct clinical situations. This workflow does not apply to:

  • Patients under age 30: While the initial imaging choice is the same (ultrasound), the pre-test probability of malignancy is lower, which can influence downstream management. This is covered in a separate ACR variant.
  • Patients requiring breast cancer screening: This guidance is for a diagnostic workup of a specific finding, not for routine screening in asymptomatic pregnant patients, even those at high risk.
  • Patients with clinically suspicious nipple discharge: This symptom has its own dedicated diagnostic pathway, as the differential diagnosis and imaging goals differ from those for a palpable mass.

Correctly identifying your patient within this specific scenario ensures the application of the most appropriate and evidence-based imaging strategy.

What Diagnoses Are You Working Up in This Scenario?

When evaluating a new breast mass during pregnancy, the differential diagnosis is broad, spanning benign physiologic changes to malignancy. The primary goal of imaging is to confidently differentiate between these possibilities.

The most critical diagnosis to exclude is pregnancy-associated breast cancer (PABC). Defined as breast cancer diagnosed during pregnancy or within one year postpartum, PABC can present with more advanced disease, partly due to diagnostic delays from attributing symptoms to normal pregnancy changes. Although relatively uncommon, its potential for aggressive behavior makes prompt and accurate evaluation essential.

More commonly, a palpable mass in this population is a benign finding related to hormonal stimulation. A galactocele, a milk-filled cyst caused by a blocked duct, is a classic finding, particularly in the third trimester and postpartum period. Similarly, a lactating adenoma is a benign tumor (a variant of a fibroadenoma) that arises from proliferative glandular tissue and is unique to pregnant and lactating individuals.

Pre-existing benign lesions like a fibroadenoma can also grow and become palpable for the first time during pregnancy due to hormonal sensitivity. Finally, infectious or inflammatory causes, such as a localized abscess or mastitis, can present as a tender, palpable mass, often with associated skin erythema and warmth.

Why Is Breast Ultrasound the Recommended Initial Study for This Presentation?

The ACR rates breast ultrasound (US) as ‘Usually Appropriate’ and the primary recommended study for a pregnant patient aged 30 or older with a palpable mass. This recommendation is rooted in its excellent safety profile and high diagnostic accuracy in this specific clinical context.

The foremost advantage of ultrasound is the complete absence of ionizing radiation (0 mSv), making it the safest imaging modality for both the patient and the fetus. Beyond safety, ultrasound excels in the dense, glandular breast tissue characteristic of pregnancy. The increased water content and decreased fat in the pregnant breast can significantly reduce the sensitivity of mammography, whereas ultrasound is less affected by these changes. It can reliably differentiate cystic from solid masses, a crucial first step in any breast workup. For solid masses, sonographic features—such as shape, margins, orientation, and vascularity—provide high sensitivity for identifying suspicious characteristics that warrant a biopsy.

While diagnostic mammography and digital breast tomosynthesis are also rated ‘Usually Appropriate’, they are typically reserved as secondary, problem-solving tools after an initial ultrasound. There are two main reasons for this sequencing:

  • Radiation Dose: Although the fetal radiation dose from a properly shielded mammogram is negligible (adult RRL ☢☢ 0.1-1mSv), the principle of ALARA (As Low As Reasonably Achievable) supports using a non-radiation modality first if it can effectively answer the clinical question.
  • Reduced Sensitivity: As mentioned, the physiologic increase in breast density during pregnancy can obscure an underlying mass on mammography, potentially leading to a false-negative result. Ultrasound is often more sensitive in this setting.

Other modalities are rated ‘Usually Not Appropriate’. MRI of the breast with and without IV contrast is avoided as a first-line tool due to the use of gadolinium-based contrast agents. Gadolinium is known to cross the placenta and enter the fetal circulation, and while no direct harm has been proven, its long-term effects on the fetus are unknown. Therefore, its use is reserved for rare, specific indications where the benefits clearly outweigh the theoretical risks.

What’s Next After Breast Ultrasound? Downstream Workflow

The results of the initial breast ultrasound will guide the subsequent steps in the patient’s management. The findings are typically categorized using the Breast Imaging Reporting and Data System (BI-RADS) score.

  • Negative or Benign Finding (BI-RADS 1 or 2): If the ultrasound shows no abnormality or a classic benign finding like a simple cyst or a typical fibroadenoma, the workup is complete. The patient can be reassured, and routine clinical follow-up is sufficient. If a galactocele is large and symptomatic, ultrasound-guided aspiration can be both diagnostic and therapeutic.
  • Suspicious Finding (BI-RADS 4 or 5): If the mass has features suspicious for malignancy (e.g., irregular shape, spiculated margins, posterior acoustic shadowing), the next step is a core needle biopsy. This procedure is safely and effectively performed under real-time ultrasound guidance. The tissue samples are then sent for pathologic analysis. A prompt referral to a breast surgeon is indicated to coordinate the biopsy and subsequent management plan.
  • Probably Benign Finding (BI-RADS 3): This category presents a unique challenge in pregnant patients. Normally, a BI-RADS 3 finding has a <2% chance of malignancy and is managed with short-term imaging follow-up (typically at 6 months). However, given that pregnancy-associated cancers can grow rapidly, many clinicians adopt a lower threshold for biopsy in this population. The decision between short-term follow-up (e.g., a repeat ultrasound in 3-6 months) and immediate biopsy should be made in consultation with a breast imaging specialist and the patient, considering the specific imaging features and patient preferences.

Pitfalls to Avoid (and When to Get Help)

Navigating a breast mass workup during pregnancy requires vigilance to avoid common diagnostic traps. The most significant pitfall is “attribution error”—dismissing a new palpable mass as a normal physiologic change of pregnancy, thereby delaying a necessary workup. Any new, persistent, or dominant palpable mass warrants imaging.

Another potential error is ordering an inappropriate initial study. Starting with a contrast-enhanced MRI, for example, unnecessarily exposes the fetus to gadolinium when ultrasound would have been sufficient. It is also critical to clearly communicate the patient’s pregnancy status and gestational age on the imaging requisition to ensure the radiology team uses appropriate protocols and considerations.

If the initial ultrasound is suspicious for malignancy (BI-RADS 4 or 5), or if there is clinical-radiologic discordance (e.g., a persistent palpable mass with a negative ultrasound), immediate escalation is warranted. This involves a referral to a breast surgeon or a multidisciplinary breast center for biopsy planning and further management.

Related ACR Topics and Tools

This article covers one specific scenario within the broader topic of breast imaging in pregnant and lactating patients. For a comprehensive overview of all related clinical variants, from screening to nipple discharge, please consult our parent guide. Additional tools can help you apply these criteria in your daily practice.

Frequently Asked Questions

Is mammography ever the right first step for a palpable mass in a pregnant patient over 30?

While both ultrasound and diagnostic mammography are rated ‘Usually Appropriate’ by the ACR for this scenario, ultrasound is the strongly preferred initial study. This is because it involves no ionizing radiation and is more sensitive in the dense breast tissue common during pregnancy. Mammography is typically reserved as a problem-solving tool if the ultrasound is inconclusive or suspicious.

What if the patient is 29 years old instead of 30?

The ACR provides a separate variant for pregnant patients under 30 with a palpable mass. The recommended initial imaging study remains breast ultrasound. The primary difference is the lower pre-test probability of malignancy in the younger age group, which may influence the threshold for biopsy versus short-term follow-up for indeterminate findings.

If a biopsy is needed, is it safe to perform during pregnancy?

Yes, an ultrasound-guided core needle biopsy is a safe and standard procedure during pregnancy. It is performed using local anesthesia (typically lidocaine without epinephrine), which has a well-established safety profile. The procedure is minimally invasive and provides a definitive tissue diagnosis, which is critical for guiding further management.

How do I handle a BI-RADS 3 (Probably Benign) finding in a pregnant patient?

This is a complex decision that requires shared decision-making. While the standard of care for a BI-RADS 3 finding is often short-term imaging follow-up, the potential for rapid tumor growth during pregnancy leads many experts to recommend a lower threshold for biopsy. The decision should be based on the specific sonographic features, patient anxiety, and a discussion with a breast radiologist.

Does a negative ultrasound rule out cancer if I can still feel a lump?

This situation is known as clinical-radiologic discordance and requires further action. While ultrasound is highly sensitive, it is not perfect. If a distinct, persistent palpable mass corresponds to a negative or benign-appearing area on ultrasound, further evaluation is warranted. This may include a repeat clinical exam, consideration of diagnostic mammography, or referral to a breast surgeon for possible excisional biopsy.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026